Parents, Pediatricians Favor Camilia in Study

A majority of parents and pediatricians were overwhelmingly satisfied with the effectiveness of Camilia in relieving their child’s teething discomfort in a study of nearly 600 children observed for seven days.

In the 2008-2009 study, 190 French pediatricians compared Camilia to two dental gels— one made with amyleine hydrochloride and the other with tamarind pulp. A total of 597 children between the ages of 3 months and 24 months were observed. Eighty-two percent of the pediatricians were satisfied with the results obtained and 71.2 percent preferred Camilia over the other two products.1

As for the parents, 77 percent said they were either satisfied or very satisfied with the efficacy of Camilia, while 85 percent said they would use Camilia again for future teething symptoms.1 Camilia is the most-prescribed teething medicine in France. It is also the top-selling medicine on the teething market in Canada,2 and 94 percent of buyers are satisfied with Camilia for their children.3

Camilia, which relieves painful gums and irritability,* is a tasteless solution that is absorbed sublingually without numbing the gums or affecting the gag reflex. Camilia is also free of benzocaine, flavors, dyes, lactose, sugar or artificial sweeteners. Camilia is also easy to give to your teething child. Parents just need to snap off one single-dose tube, twist the cap, and squeeze the entire contents of the single-dose container into the child’s mouth.

“Camilia is the most-prescribed teething medicine in France. It is also the top-selling medicine on the teething market in Canada[…]2

Reference: Stagnara J., Besse P, El Kebir S, Bordet MF. Symptoms associated with teething and response to three treatments, including homeopathic medicine: a multicenter prospective observational study among 190 French pediatricians. Minerva Pediatrica, 2016 Sept. 21.

1The above statements are supported by an observational study, and therefore may be subject to inherent study-related limitations, including the potential for bias. All results reflect the pediatricians and parents surveyed and are not necessarily transferrable to a larger or different population or cohort. Results may not reflect a comparison to other drugs that are available in the United States.

2 Sources: Neilsen Canada 52 weeks – toothache drops – 5 Vol (November 2016)

3 CSA Research – May 2016 – Base: 507 buyers of Camilia (203 in France, 201 in Poland, and 103 in Russia).

 
Bitnami